- Home
- SEED vs BCDA Comparison
SEED vs BCDA Comparison
Compare SEED & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- BCDA
- Stock Information
- Founded
- SEED 1997
- BCDA N/A
- Country
- SEED China
- BCDA United States
- Employees
- SEED N/A
- BCDA N/A
- Industry
- SEED Farming/Seeds/Milling
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- BCDA Health Care
- Exchange
- SEED Nasdaq
- BCDA Nasdaq
- Market Cap
- SEED 10.7M
- BCDA 11.0M
- IPO Year
- SEED N/A
- BCDA N/A
- Fundamental
- Price
- SEED $1.05
- BCDA $2.15
- Analyst Decision
- SEED
- BCDA Strong Buy
- Analyst Count
- SEED 0
- BCDA 1
- Target Price
- SEED N/A
- BCDA $25.00
- AVG Volume (30 Days)
- SEED 67.3K
- BCDA 52.3K
- Earning Date
- SEED 06-26-2025
- BCDA 08-12-2025
- Dividend Yield
- SEED N/A
- BCDA N/A
- EPS Growth
- SEED N/A
- BCDA N/A
- EPS
- SEED N/A
- BCDA N/A
- Revenue
- SEED $12,910,081.00
- BCDA $3,000.00
- Revenue This Year
- SEED N/A
- BCDA N/A
- Revenue Next Year
- SEED N/A
- BCDA N/A
- P/E Ratio
- SEED N/A
- BCDA N/A
- Revenue Growth
- SEED 21.51
- BCDA N/A
- 52 Week Low
- SEED $0.98
- BCDA $1.63
- 52 Week High
- SEED $4.99
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- SEED 56.42
- BCDA 51.13
- Support Level
- SEED $0.98
- BCDA $1.98
- Resistance Level
- SEED $1.61
- BCDA $2.45
- Average True Range (ATR)
- SEED 0.11
- BCDA 0.17
- MACD
- SEED 0.03
- BCDA 0.01
- Stochastic Oscillator
- SEED 42.86
- BCDA 53.19
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).